Latest Development Pipeline News

Arena REIT has delivered a strong half-year 2025 performance, with significant profit growth driven by strategic acquisitions and development completions, while reaffirming its distribution guidance and sustainability commitments.

Arena REIT delivered a robust HY2025 performance with statutory net profit soaring 87%, underpinned by strategic acquisitions and development completions. The REIT reaffirmed its FY2025 distribution guidance, signaling confidence in sustained growth amid a strong social infrastructure portfolio.

Dexus Convenience Retail REIT (ASX: DXC) reported steady half-year results for 2025, underpinned by active portfolio management and ongoing redevelopment projects. The fund remains on track to meet full-year guidance while enhancing income security and growth potential.

Garda Property Group has reaffirmed its FY25 income return at 7.2 cents per security and upgraded its distribution payout ratio to 95% of FFO. The group plans to sell its North Lakes industrial site for $114 million and is marketing its Cairns Corporate Tower, aiming to reduce gearing and reposition as a focused industrial REIT.

Biome Australia has partnered with the Food and Beverage Accelerator (FaBA) to jointly develop its promising BMB18 probiotic strain, leveraging $50 million in Australian government funding while retaining full IP ownership.

Argent BioPharma reports strategic cost-cutting moves including facility closures and delisting from the LSE, while securing German distribution approval and raising significant capital to support its drug pipeline.

Caprice Resources has launched a 5,000m drilling program at its Island Gold Project and expanded its West Arunta copper-niobium exploration tenure, supported by a $2.5 million capital raise. The company is sharpening its focus on high-grade gold assets in the Murchison goldfields while advancing large-scale greenfield projects.

Cedar Woods Properties has successfully extended its $330 million corporate finance facility, pushing the maturity of its three-year tranche to 2028 and its five-year tranche to 2030, reinforcing its financial stability.

RooLife Group Ltd (ASX:RLG) reports a remarkable 144% jump in Q2 FY25 sales revenue, driven by new online stores and strategic market entries into China and India. The company’s own branded health and wellness products are central to its growth strategy.

Chimeric Therapeutics has dosed the first three patients in its Phase 1/2 CHM CDH17 CAR-T trial targeting gastrointestinal cancers, alongside advancing its AML and NK cell therapy programs. The company also secured $5 million in funding and appointed Dr Rebecca McQualter as CEO.

Comet Ridge has made significant strides in its Mahalo Gas Hub development, approving upstream FEED and progressing pipeline connections, supported by a strong cash position of $19.3 million. These developments position the company to address Australia's tightening east coast gas market.

Race Oncology has advanced its Phase 1 clinical trial for RC220, submitting ethics approvals and bolstering its cash reserves to $18.78 million following a $5.25 million R&D tax incentive.